Month: September 2026

BPCE S.A.
Legal Entity Identifier (LEI): 9695005MSX1OYEMGDF46

Société anonyme à directoire et conseil de surveillance

Share capital: €242 487 090

Registered office: 7, promenade Germaine Sablon, 75013 Paris, France

RCS Paris 493 455 042

(the « Issuer »)

NOTICE OF EARLY REDEMPTION TO THE NOTEHOLDERS

dated 11 September 2026

in relation to the

BPCE €900,000,000 Contingent Tier 2 Capital Subordinated Fixed Rate Resettable Notes due January 2042 issued as Series no.: 2021-13

(ISIN: FR0014005V34) (the “Notes”)

On 13 October 2021, the Issuer issued the Notes with a prospectus dated 11 October 2021 which received approval no. 21-438 from the Autorité des marchés financiers (the “Prospectus”), which includes the terms and conditions of the Notes (the “Conditions”). Capitalized terms not specifically defined in this notice shall have the meaning given to them in the Conditions.

Notice is hereby given that, pursuant to Condition 7.2 (Redemption at the option of the Issuer) of the Conditions, the Issuer will redeem the Notes in full on 13 October 2026 (the “Optional Redemption Date” ).

An Euronext Paris notice regarding the delisting of the Notes will be published, with effect on such date accordingly.

At the Optional Redemption Date, the Issuer will pay to each noteholder the principal amount of such Notes together with any interest accrued up to (but excluding) the Optional Redemption Date (the “Optional Redemption Amount”).

Fiscal Agent, Principal Paying Agent and Calculation Agent:

BNP PARIBAS (acting through its Securities Services business)

Les Grands Moulins de Pantin

9, rue du Débarcadère

93500 Pantin

France

By: BPCE

Attachment

• Redemption notice Contingent Tier 2 series 2021_13 (call 13 10 2026)

Press Release

Nicox Announces NCX 470 NDA in China Accepted for Review

Acceptance of the NCX 470 dossier initiates the review process Regulatory decision expected within 12-18 months from the August submission Q&A on Ocumension available on Nicox’s website September 11, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive licensee in China, Ocumension Therapeutics, has received confirmation from China’s National Medical Products Administration (NMPA) that the NCX 470 (also referred to as OT-301 by Ocumension) New Drug Application (NDA) in China has been accepted for review. This acceptance initiates the review of the NDA by the NMPA. Nicox had previously announced the submission of the NCX 470 NDA in China as a treatment to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. “The acceptance for review of the NCX 470 NDA in China initiates the examination process and is another key step towards its commercialisation in this territory. We look forward to continuing to work with the Ocumension team as they prepare for a future launch.” said Gavin Spencer, Chief Executive Officer of Nicox. Ocumension’s Press release is here. Ocumension has paid Nicox license fees of €18 million for the rights to develop and commercialise NCX 470 in the Chinese, Korean and Southeast Asian markets, contributed 50% of the Denali clinical trial costs and is one of Nicox’s principal shareholders. Nicox will receive tiered royalties on sales of NCX 470 made by Ocumension ranging from 6% to 12%. Ocumension already has an ophthalmology sales force in place throughout China and is therefore well-positioned for a rapid launch of NCX 470. There is no fixed period for approval of a pharmaceutical product in China, however the review process typically takes 12 to 18 months following submission. The decision on NCX 470 in China is expected after the decision by the U.S. FDA, who have assigned the PDUFA date1 for 30 April 2027.   Key Upcoming NCX 470 Milestones Japan Phase 3 clinical trials results: trials ongoing   NDA approval in the U.S.: PDUFA date 30 April 2027 U.S. Launch: expected in H2 2027, subject to NDA approval NDA decision in China: Submission made in August 2026, accepted for review on 10 September 2026

About NCX 470

NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signalling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs. NCX 470 has completed two Phase 3 clinical trials designed to fulfil the regulatory requirements for safety and efficacy to support NDA submissions in the U.S. and China, Mont Blanc and Denali. Both trials were positive and met the efficacy endpoints necessary for submission of a New Drug Application in the United States and China. NDAs for NCX 470 have been submitted in the U.S. and China. NCX 470 is an investigational product and has not yet been approved by the FDA. About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world.  Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.com

Analyst coverage
H.C. Wainwright & Co        Yi Chen           New York, U.S.
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts
Nicox Gavin Spencer Chief Executive Officer T +33 (0)4 97 24 53 00 communications@nicox.com
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2025” which are available on Nicox’s website (www.nicox.com). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.
Nicox S.A. Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France T +33 (0)4 97 24 53 00

---

1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA).

Attachment

• EN_NCX470ChinaNDAAcceptanceSeptempber2026_PR_FINAL

Lille (France), Cambridge (Massachusetts, United States), September 11, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit GENFIT to the CAC Mid 60 and SBF 120 indices.

These changes will become effective after the market closes on Friday, September 18, 2026.

Pascal Prigent, CEO of GENFIT, commented: “We are pleased to be added to the Euronext CAC Mid 60 and SBF 120 indices. This inclusion comes after a positive momentum for GENFIT and growing investor confidence in our strategy and our ability to execute on it. This milestone further validates our continued commitment to bringing innovative therapies and diagnostic solutions to patients with rare and life-threatening liver diseases while creating long-term value for our shareholders.”

The CAC Mid 60 and SBF 120 are among the most widely-followed indices on Euronext Paris, representing mid-sized listed companies and a broader selection of 120 major securities, respectively. The company’s admission to the SBF 120 reflects its increased market capitalization, liquidity and visibility. It is expected to enhance the company’s profile among institutional investors and confirms its growing relevance within the French equity market.

END

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.¹   Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding the expected benefits of GENFIT’s inclusion in the CAC Mid 60 and SBF 120 indices, investor interest in the Company, the Company’s strategic positioning, its ability to execute on its strategy, its future growth prospects, the advancement of its pipeline and the creation of long-term value for shareholders. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Inclusion in stock market indices does not guarantee increased liquidity, sustained investor interest, share price appreciation or future operating performance. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.fr) and the AMF’s website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACTS

GENFIT | Investors

Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 |
jean-christophe.marcoux@genfit.com

Kevin Gardner – Life Science Advisors | kgardner@lifesciadvisors.com

GENFIT | Media

Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com 

---

1 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®

Attachment

• GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

NOTICE

Elis announces the early redemption on 13 October 2026 of its €380,000,000 2.25% bonds convertible into new shares and/or exchangeable for existing shares
due 2029 (OCEANEs)
ISIN FR001400AFJ9 (the “Bonds”)

Puteaux, September 11, 2026 – Elis (the “Company”) informs the holders of the Bonds (the “Bondholders”) that it will proceed with the early redemption on 13 October 2026 (the “Early Redemption Date”) of all Bonds outstanding on such date, pursuant to the first paragraph of Condition 1.10.1.3, “Early redemption at the Company’s option”, of the terms and conditions of the Bonds dated 22 September 2022 (the “Terms and Conditions”).

Capitalised terms that are not otherwise defined in this notice shall have the meanings given to them in the Terms and Conditions.

Unless the Bondholders exercise their Conversion/Exchange Right in accordance with the Terms and Conditions, the Company will redeem in cash on the Early Redemption Date each Bond outstanding on such date at a price per Bond equal to EUR 100,129.45 (the “Early Redemption Price”), being the par value of each Bond (EUR 100,000) together with EUR 129.45 in accrued interest calculated from (and including) 22 September 2026 to (but excluding) the Early Redemption Date.

In accordance with the first paragraph of Condition 1.10.1.3 of the Terms and Conditions, at the Company’s request, Conv-Ex Advisors Limited, acting as Calculation Agent in respect of the Bonds, has verified that the arithmetic mean, calculated over a period of 20 consecutive Trading Days from (and including) 11 August 2026 to (and including) 7 September 2026, selected by the Company from among the 40 consecutive Trading Days from (and including) 17 July 2026 to (and including) 10 September 2026, of the products, in respect of each such Trading Day, of (i) the Volume-Weighted Average Price of the Shares on that Trading Day and (ii) the Conversion/Exchange Ratio applicable on that Trading Day, exceeded 130% of the par value of each Bond.

In accordance with Conditions 1.10.1.3 and 2.3 of the Terms and Conditions, a Bondholder may exercise its Conversion/Exchange Right in respect of any Bond held by it, provided that the relevant Request Date in respect of such exercise falls no later than 2 October 2026 (being the seventh (7^th) Business Day preceding the Early Redemption Date), and that such exercise is otherwise made in accordance with the Terms and Conditions.

Bondholders wishing to exercise their Conversion/Exchange Right should contact the financial intermediary holding their Bonds in a securities account sufficiently in advance so that all requirements for a valid exercise, including receipt of the exercise request and transfer of the corresponding Bonds, are completed by the applicable deadline. The centralising agent for the Bonds is Uptevia, Cœur Défense Tour A – 90-110 Esplanade du Général de Gaulle 92400 Courbevoie (the “Centralising Agent”).

Each Bond in respect of which the Conversion/Exchange Right has not been validly exercised by the applicable deadline will be redeemed in cash at the Early Redemption Price on the Early Redemption Date.

As of the date of this notice, 3,800 Bonds remain outstanding out of a total of 3,800 Bonds initially issued. The Conversion/Exchange Ratio is currently equal to 6,256.8564 Shares per Bond. Assuming that all Bondholders exercise their Conversion/Exchange Right, a maximum of 23,776,054 Elis shares could be delivered, representing approximately 10.21% of the Company’s current share capital, subject to any subsequent adjustment of the Conversion/Exchange Ratio in accordance with the Terms and Conditions. The Company intends to use the existing Shares it holds following the completion of its share buyback program on 9 July 2026, thereby limiting the number of newly issued Shares that may be required. Bondholders validly exercising their Conversion/Exchange Right may receive newly issued Shares and/or existing Shares, as determined by the Company. Settlement and delivery of Shares will occur in accordance with the Terms and Conditions and the instructions of the Centralising Agent.

IMPORTANT NOTICE

The early redemption of the Bonds may not be accepted in any jurisdiction where such redemption would be prohibited or restricted by applicable law, or by residents of any such jurisdiction. No document relating to the exercise of the early redemption option may be transmitted, directly or indirectly, in or into any such jurisdiction or to any such person.

This notice does not constitute an offer to sell, a solicitation of an offer to purchase, or an offer to purchase any securities of Elis in any jurisdiction.

Contacts

Nicolas Buron
Director of Investor Relations, Financing & Treasury
Phone: + 33 (0)1 75 49 98 30 – nicolas.buron@elis.com

Charline Lefaucheux
Investor Relations
Phone: + 33 (0)1 75 49 98 15 – charline.lefaucheux@elis.com

Attachment

• Elis announces the early redemption on 13 October 2026 of its bonds convertible